Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · as published 2026-01-23 View official record Methodology

Covered recipient · General Payments record

MARY GAFFNEY

Allopathic & Osteopathic Physicians Family Medicine

NPI
1467569483
CMS profile
202974
Location
CHARLOTTE, NC

General Payments · PY2018–2024

$7,187.36

  • Reported across 250 records
  • CMS publication 2026-01-23

Latest program year · PY2024

$1,085.17

34 records · 0 disputed

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How these totals are calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

PY2024 · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,085.17 34

By paying entity

PY2024 · sorted by reported total

Paying entityAmountRecords
Acerta Pharma LLC $254.68 3
Novo Nordisk AS $202.05 4
ABBVIE INC. $175.07 5
Bayer HealthCare Pharmaceuticals Inc. $147.75 6
Orexo US, Inc. $100.01 5
PFIZER INC. $57.69 3
Lilly USA, LLC $51.93 3
Indivior Inc. $38.59 2
SHIELD THERAPEUTICS INC $21.11 1
Boehringer Ingelheim Pharmaceuticals, Inc. $19.98 1
DEXCOM, INC. $16.31 1

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2018 $351.59 22
PY2019 $2,263.64 44
PY2020 $554.74 24
PY2021 $962.73 39
PY2022 $884.44 49
PY2023 $1,085.05 38
PY2024 $1,085.17 34

Payment records · PY2024 (34)

Sorted by paying entity, then date · as published by CMS

Program year 2024 201820192020202120222023 Record-level detail is published for PY2024; earlier years are summarised in “By program year”.
Paying entity Amount Date Nature of payment Dispute status Published Record ID Source
ABBVIE INC. $119.53 03/07/2024 Food and Beverage Undisputed 01/23/2026 1103764028 CMS
ABBVIE INC. $16.66 05/03/2024 Food and Beverage Undisputed 01/23/2026 1103764030 CMS
ABBVIE INC. $8.89 05/17/2024 Food and Beverage Undisputed 01/23/2026 1103764032 CMS
ABBVIE INC. $5.90 10/29/2024 Food and Beverage Undisputed 01/23/2026 1103764034 CMS
ABBVIE INC. $24.09 10/29/2024 Food and Beverage Undisputed 01/23/2026 1103764036 CMS
AstraZeneca Pharmaceuticals LP $173.08 01/16/2024 Food and Beverage Undisputed 01/23/2026 1105746911 CMS
AstraZeneca Pharmaceuticals LP $20.65 02/26/2024 Food and Beverage Undisputed 01/23/2026 1104262849 CMS
AstraZeneca Pharmaceuticals LP $60.95 09/26/2024 Food and Beverage Undisputed 01/23/2026 1105887199 CMS
Bayer Healthcare Pharmaceuticals Inc. $7.34 01/10/2024 Food and Beverage Undisputed 01/23/2026 1086086671 CMS
Bayer Healthcare Pharmaceuticals Inc. $9.98 03/13/2024 Food and Beverage Undisputed 01/23/2026 1086087121 CMS
Bayer Healthcare Pharmaceuticals Inc. $103.89 04/12/2024 Food and Beverage Undisputed 01/23/2026 1086147607 CMS
Bayer Healthcare Pharmaceuticals Inc. $10.74 05/13/2024 Food and Beverage Undisputed 01/23/2026 1086092469 CMS
Bayer Healthcare Pharmaceuticals Inc. $8.72 07/09/2024 Food and Beverage Undisputed 01/23/2026 1086085457 CMS
Bayer Healthcare Pharmaceuticals Inc. $7.08 10/22/2024 Food and Beverage Undisputed 01/23/2026 1086081688 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.98 11/11/2024 Food and Beverage Undisputed 01/23/2026 1118021578 CMS
Dexcom, Inc. $16.31 06/25/2024 Food and Beverage Undisputed 01/23/2026 1153320474 CMS
Indivior Inc. $15.94 02/21/2024 Food and Beverage Undisputed 01/23/2026 1144528032 CMS
Indivior Inc. $22.65 04/08/2024 Food and Beverage Undisputed 01/23/2026 1144528034 CMS
Lilly USA, LLC $13.84 01/22/2024 Food and Beverage Undisputed 01/23/2026 1135169862 CMS
Lilly USA, LLC $18.55 05/01/2024 Food and Beverage Undisputed 01/23/2026 1135181602 CMS
Lilly USA, LLC $19.54 07/15/2024 Food and Beverage Undisputed 01/23/2026 1135169864 CMS
Novo Nordisk Inc $50.00 03/29/2024 Food and Beverage Undisputed 01/23/2026 1097318435 CMS
Novo Nordisk Inc $87.69 04/04/2024 Food and Beverage Undisputed 01/23/2026 1097834576 CMS
Novo Nordisk Inc $19.72 07/16/2024 Food and Beverage Undisputed 01/23/2026 1097718361 CMS
Novo Nordisk Inc $44.64 11/19/2024 Food and Beverage Undisputed 01/23/2026 1097128954 CMS
Orexo US, Inc. $23.38 01/23/2024 Food and Beverage Undisputed 01/23/2026 1136176483 CMS
Orexo US, Inc. $24.97 04/17/2024 Food and Beverage Undisputed 01/23/2026 1136179056 CMS
Orexo US, Inc. $19.00 05/30/2024 Food and Beverage Undisputed 01/23/2026 1136176994 CMS
Orexo US, Inc. $16.71 07/10/2024 Food and Beverage Undisputed 01/23/2026 1136178604 CMS
Orexo US, Inc. $15.95 08/21/2024 Food and Beverage Undisputed 01/23/2026 1136176996 CMS
PFIZER INC. $13.45 02/27/2024 Food and Beverage Undisputed 01/23/2026 1131135063 CMS
PFIZER INC. $29.13 10/07/2024 Food and Beverage Undisputed 01/23/2026 1130879816 CMS
PFIZER INC. $15.11 11/04/2024 Food and Beverage Undisputed 01/23/2026 1132123959 CMS
SHIELD THERAPEUTICS INC $21.11 11/09/2024 Food and Beverage Undisputed 01/23/2026 1150153328 CMS

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-01-23
Program years on this page
2018, 2019, 2020, 2021, 2022, 2023, 2024
Source files
Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.